Read about Endologix
in the news

Embrace the evidence.

The Latest:

Endologix Announces 36-Month Results of DETOUR2 Study at 2024 VIVA Late-Breaking Clinical Trial Session

See Release

All News

Archives

Endologix Announces Equity Financing of $52 Million and Debt Restructuring Addressing 2020 Maturities and Financial Covenants

Endologix Provides Update on Previously Announced Voluntary Nellix System Recall

Endologix Appoints John D. Zehren as Chief Commercial Officer

Endologix Takes Decisive Action to Optimize Patient Outcomes by Ensuring Nellix System Used Only within Current Indications

Endologix Honors Innovators of Aortic Therapy at VEITHsymposium